ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
GSK decides to halt mid-stage feladilimab studies pharmatimes
April 16, 2021GlaxoSmithKline (GSK) has announced that it will stop enrolling patients into trials evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab.
Pharma Sources Insight January 2025
